1. Inhibition of mitochondrial over-division by (+)-14,15-Dehydrovincamine attenuates cisplatin-induced acute kidney injury via the JNK/Mff pathway.
- Author
-
Hu JW, Xiao JJ, Cai S, Zhong Y, Wang S, Liu S, Wu X, Cai Y, and Zhang BF
- Subjects
- Animals, Mice, Mitochondrial Dynamics drug effects, Dynamins metabolism, Dynamins genetics, JNK Mitogen-Activated Protein Kinases metabolism, JNK Mitogen-Activated Protein Kinases genetics, Humans, MAP Kinase Signaling System drug effects, Male, Epithelial Cells drug effects, Epithelial Cells metabolism, Epithelial Cells pathology, Signal Transduction drug effects, Mitochondrial Proteins metabolism, Mitochondrial Proteins genetics, Disease Models, Animal, Kidney Tubules pathology, Kidney Tubules drug effects, Kidney Tubules metabolism, Acute Kidney Injury chemically induced, Acute Kidney Injury drug therapy, Acute Kidney Injury pathology, Acute Kidney Injury metabolism, Cisplatin adverse effects, Apoptosis drug effects, Mitochondria drug effects, Mitochondria metabolism, Mitochondria pathology
- Abstract
Cisplatin-induced acute kidney injury (AKI) is characterized by mitochondrial damage and apoptosis, and safe and effective therapeutic agents are urgently needed. Renal tubular epithelial cells, the main site of AKI, are enriched with a large number of mitochondria, which are crucial for the progression of AKI with an impaired energy supply. Vincamine has anti-inflammatory and antioxidant effects in mouse AKI models. As a natural compound derived from Tabernaemontana pandacaqui, (+)-14, 15-Dehydrovincamine and Vincamine differ in structure by only one double bond, and the role and exact mechanism of (+)-14, 15-Dehydrovincamine remains to be elucidated in AKI. The present study demonstrated that (+)-14,15-Dehydrovincamine significantly ameliorated mitochondrial dysfunction and maintained mitochondrial homeostasis in a cisplatin-induced AKI model. Furthermore, (+)-14,15-Dehydrovincamine ameliorates cytochrome C-dependent apoptosis in renal tubular epithelial cells. c-Jun NH2-terminal kinase (JNK) was identified as a potential target protein of (+)-14,15-Dehydrovincamine attenuating AKI by network pharmacological analysis. (+)-14,15-Dehydrovincamine inhibited cisplatin-induced JNK activation, mitochondrial fission factor (Mff) phosphorylation, and dynamin-related protein 1 (Drp1) translocation to the mitochondria in renal tubular epithelial cells. Meanwhile, the JNK activator anisomycin restored Mff phosphorylation and Drp1 translocation, counteracting the protective effect of (+)-14,15-Dehydrovincamine on mitochondrial dysfunction in cisplatin-induced TECs injury. In conclusion, (+)-14,15-Dehydrovincamine reduced mitochondrial fission, maintained mitochondrial homeostasis, and attenuated apoptosis by inhibiting the JNK/Mff/Drp1 pathway, which in turn ameliorated cisplatin-induced AKI., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF